Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Califf's Priorities Feature Short- And Long-Term Goals Despite Potentially Brief Tenure

This article was originally published in The Tan Sheet

Executive Summary

Newly confirmed FDA Commissioner Robert Califf should not assume he will be leaving once a new president arrives, a Republican-appointed predecessor says. Industry trade groups ask Califf to make supplement industry regulation an early priority.


Related Content

Trump’s Election Could Bring ‘Best Of Times’ For Pharma
Finally … Rachel Sherman Takes Califf's Old FDA Job
Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
FDA Mandates Need Accompanying Resources, Hamburg Says